Clinical Trials

Under the sponsorship of Pharmazz Inc., Centhaquin has been evaluated in multiple clinical trials, including a completed Phase I study assessing safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects, as well as a completed Phase II study investigating its safety and efficacy as a resuscitative agent for hypovolemic shock resulting from blood loss. With recruitment fully completed across these studies, Centhaquin has established an early-to-mid-stage clinical profile, supporting its focused development as a specialized resuscitation therapy for acute hypovolemic conditions.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04056065 Completed
Hypovolemic Shock|Blood Loss
Pharmazz Inc.
2017-05-29 Phase 2
NCT02408731 Completed
Healthy
Pharmazz Inc.
2014-10 Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Centhaquin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Centhaquin acts by engaging cardiovascular adrenergic signaling pathways to modulate systemic vascular tone, thereby reducing systemic vascular resistance and improving venous return. This intracellular hemodynamic shift enhances myocardial efficiency and augments cardiac output, providing crucial hemodynamic stabilization required during resuscitative management of hypovolemic shock induced by severe blood loss.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.